These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 19534569)

  • 1. Virus maturation as a new HIV-1 therapeutic target.
    Adamson CS; Salzwedel K; Freed EO
    Expert Opin Ther Targets; 2009 Aug; 13(8):895-908. PubMed ID: 19534569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Maturation: Lessons Learned from Inhibitors.
    Kleinpeter AB; Freed EO
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32858867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation.
    Novikova M; Adams LJ; Fontana J; Gres AT; Balasubramaniam M; Winkler DC; Kudchodkar SB; Soheilian F; Sarafianos SG; Steven AC; Freed EO
    mBio; 2018 Oct; 9(5):. PubMed ID: 30327442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Capsid Inhibitors as Antiretroviral Agents.
    Thenin-Houssier S; Valente ST
    Curr HIV Res; 2016; 14(3):270-82. PubMed ID: 26957201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process.
    Adamson CS
    Mol Biol Int; 2012; 2012():604261. PubMed ID: 22888428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle.
    Jiang Y; Liu X; De Clercq E
    Curr Med Chem; 2011; 18(1):16-28. PubMed ID: 21110817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.
    Urano E; Ablan SD; Mandt R; Pauly GT; Sigano DM; Schneider JP; Martin DE; Nitz TJ; Wild CT; Freed EO
    Antimicrob Agents Chemother; 2016 Jan; 60(1):190-7. PubMed ID: 26482309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396.
    Murgatroyd C; Pirrie L; Tran F; Smith TK; Westwood NJ; Adamson CS
    J Virol; 2016 Sep; 90(18):8181-97. PubMed ID: 27384665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV type 1 Gag as a target for antiviral therapy.
    Waheed AA; Freed EO
    AIDS Res Hum Retroviruses; 2012 Jan; 28(1):54-75. PubMed ID: 21848364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.
    Spearman P
    Curr Top Med Chem; 2016; 16(10):1154-66. PubMed ID: 26329615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant Negative MA-CA Fusion Protein Is Incorporated into HIV-1 Cores and Inhibits Nuclear Entry of Viral Preintegration Complexes.
    Anderson-Daniels J; Singh PK; Sowd GA; Li W; Engelman AN; Aiken C
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electron cryotomography studies of maturing HIV-1 particles reveal the assembly pathway of the viral core.
    Woodward CL; Cheng SN; Jensen GJ
    J Virol; 2015 Jan; 89(2):1267-77. PubMed ID: 25392219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity.
    Abdurahman S; Végvári A; Youssefi M; Levi M; Höglund S; Andersson E; Horal P; Svennerholm B; Balzarini J; Vahlne A
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3737-44. PubMed ID: 18644965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of an HIV-1 maturation inhibitor on the structure and dynamics of CA-SP1 junction helices in virus-like particles.
    Gupta S; Louis JM; Tycko R
    Proc Natl Acad Sci U S A; 2020 May; 117(19):10286-10293. PubMed ID: 32341150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly.
    Reed JC; Solas D; Kitaygorodskyy A; Freeman B; Ressler DTB; Phuong DJ; Swain JV; Matlack K; Hurt CR; Lingappa VR; Lingappa JR
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33148797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein.
    Nangola S; Urvoas A; Valerio-Lepiniec M; Khamaikawin W; Sakkhachornphop S; Hong SS; Boulanger P; Minard P; Tayapiwatana C
    Retrovirology; 2012 Feb; 9():17. PubMed ID: 22348230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.
    Nguyen AT; Feasley CL; Jackson KW; Nitz TJ; Salzwedel K; Air GM; Sakalian M
    Retrovirology; 2011 Dec; 8():101. PubMed ID: 22151792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
    Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
    J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral inhibition of the HIV-1 capsid protein.
    Tang C; Loeliger E; Kinde I; Kyere S; Mayo K; Barklis E; Sun Y; Huang M; Summers MF
    J Mol Biol; 2003 Apr; 327(5):1013-20. PubMed ID: 12662926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA and Nucleocapsid Are Dispensable for Mature HIV-1 Capsid Assembly.
    Mattei S; Flemming A; Anders-Össwein M; Kräusslich HG; Briggs JA; Müller B
    J Virol; 2015 Oct; 89(19):9739-47. PubMed ID: 26178992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.